Amgen at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Amgen exhibits at Booth 3438 at ASH 2026 in New Orleans. Amgen supports a symposium on acute lymphoblastic leukemia and the order in which to use its treatments. Experts debate the path from asparaginase to cellular therapy now that minimal residual disease testing guides decisions.
| Organization | ASH 2026 Attendance |
|---|---|
Amgen Thousand Oaks, CA | |
Biotechnology company, founded in 1980, that discovers, develops and manufactures human therapeutics for serious illnesses, including blood cancers. | Booth Exhibiting at Booth 3438 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era Ordering acute lymphoblastic leukemia therapies, from asparaginase to bispecifics and CAR-T, guided by sensitive residual disease testing. |
Find decision makers at Amgen
Tell us what you sell and we’ll find the people at Amgen most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction